1.急慢性肝炎、肝硬化
2.惡性肝腫瘤(局部腫瘤燒灼術1000例以上經驗)
3.一般胃腸膽胰疾病及內視鏡治療
(疑似肝腫瘤病患，若持轉診單，可不需預先掛號，於周三上午10點以前至現場掛號2519肝癌特診。)

中華民國內科專科醫師
台中榮總一般內科主治醫師
台中榮總胃腸肝膽科主治醫師
中華民國消化系內科專科醫師
中華民國內視鏡專科醫師
中華民國醫用超音波學會專業認証醫師
肝癌專科醫師
肝腫瘤射頻消融專業醫師
台灣消化系內科專科醫師訓練醫院指導醫師
台灣消化系內視鏡專科醫師訓練醫院指導醫師

台中榮總內科部住院醫師
台中榮總胃腸肝膽科總醫師
台中榮總一般內科主治醫師
台中榮總胃腸肝膽科主治醫師
台灣肝臟研究學會會員(台肝證字第189號)
Editorial board member or reviewer of academic journals: Clinical Gastroenterology & Hepatology, Alimentary Pharmacology & Therapeutics, Scientific Reports, PLoS ONE, Journal of Gastroenterology & Hepatology, BMC Gastroenterology, Drug Design, Development and Therapy, World Journal of Gastroenterology, Experimental and Therapeutic Medicine, Translational Cancer Research, World Journal of Surgical Oncology, Advances in Digestive Medicine.

中國醫藥大學醫學士
工業工程與經營資訊學系高階醫務工程與管理碩士(學行優良獎)
中國醫藥大學臨床醫學研究所博士

中華民國醫師：醫字第031179號
內科專科醫師：內專醫字第006364號
消化系內科專科醫師：台消內專科證字第1129號
消化系內視鏡專科醫師：台消內鏡專科證字第941318號
消化系超音波專業認證醫師：中超專業證字第eG-000726號
肝癌專科醫師：台肝癌專科證字第0029號
肝腫瘤射頻消融專業醫師：台腫消專業證字第105032號

國防醫學大學醫學系臨床副教授
中山醫學大學醫學系教育部部定副教授

肝炎、肝硬化、肝癌、消化道腫瘤
台中榮總年度優良論文獎2017, 2018, 2019, 2020, 2021

1. Lee TY, Lien HC. Risk factors of Barrett’s esophagus in Taiwan. 2004. TCVGH-933303A.
2. Lee TY. Prognostic Factors of Severe Acute Exacerbation of Chronic Hepatitis B under Lamivudine Monotherapy. TCVGH-973301A.
3. Study in Asia of the Combination of TACE with Sorafenib in Patients with Hepatocellular Carcinoma (SACTS trial)
4. A Multinational, Randomized, Open-label, Phase 3 Study of Sunitinib Malate versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma

1. Lee TY, Hsu YC, Tseng HC, Lin JT, Wu MS, Wu CY*. Association of Daily Aspirin Therapy with Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. JAMA Intern Med. 2019 May 1;179(5):633-640.
2. Lee TY, Hsu YC, Tseng HC, Lin JT, Wu MS, Wu CY*. Association of Daily Aspirin Therapy with Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Virus Infection. Clin Gastroenterol Hepatol. 2020 Nov;18(12):2784-2792.
3. Tsai HJ, Chuang YW, Yang SS, Chang YZ, Chang HR*, Lee TY*. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease. J Viral Hepat. 2021 Nov;28(11):1579-1586.
4. Lai CY, Yang SS, Lee SW, Tsai HJ, Lee TY*. Cessation of Nucleos(t)ide Analogue Therapy in Non-cirrhotic Hepatitis B Patients with Prior Severe Acute Exacerbation. J Clin Med. 2021 Oct 23;10(21):4883.
5. Chi SF, Lai CY, Dong WT, Wang JM, Wang YY, Yang SS, Lin JT, Lee TY*. Establishing the blood reference interval of pancreatic elastase-1: A prospective study. J Gastroenterol Hepatol. 2022 Jan;37(1):117-123.
6. Lai PC, Chen CH, Jeng LB, Yu TM, Tsai SF, Wu MJ, Cheng SB, Yang SS, Lee TY*. Grazoprevir/Elbasvir treatment in liver or kidney transplant recipients with genotype-1b hepatitis C virus infection. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0200321.
7. Lee SW, Yang SS, Lien HC, Peng YC, Ko CW, Lee TY*. Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population. J Clin Med. 2022 Mar 6;11(5):1444.
8. Lee SW, Yang SS, Lien HC, Peng YC, Tung CF, Lee TY*. The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma. J Clin Med. 2022 Mar 6;11(5):1444.
9. Chen LS, Lee SW, Yang SS, Tsai HJ, Lee TY*. Advances in the era of direct-acting antivirals for hepatitis C in patients with unresectable hepatocellular carcinoma. Dig Dis. 2022;40(5):616-624.
10. Lee TY.* Hormone replacement therapy and risk of hepatocellular carcinoma. Adv Dig Med. 2022 June;9(2):73–74.
11. Lee SW, Yen CL, Cheng YC, Shun Yang S, Lee TY*. The radiological prognostic factors of transcatheter arterial chemoembolization to hepatocellular carcinoma. Medicine (Baltimore). 2022 Oct 14;101(41):e30875.
12. Lee SW, Chen LS, Yang SS, Huang YH, Lee TY*. Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma. Viruses. 2022 Oct 22;14(11):2316.
13. Lee PH, Huang YH, Hsu YW, Chen KC, Hsu KH, Lin H, Lee TY*, Tseng JS*, Chang GC, Yang TY. Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment. J Clin Med. 2022 Dec 28;12(1):231.
14. Tsai HJ, Wu MJ, Chen CH, Yang SS, Huang YH, Chang YZ, Chang HR*, Lee TY*. Risk Stratification for Hepatitis B Virus Reactivation in Kidney Transplant Recipients With Resolved HBV Infection. Transpl Int. 2023 Apr 13;36:11122
15. Lee TY, Hsu YC, Ho HJ, Lin JT, Chen YJ, Wu CY*. Daily aspirin associated with a reduced risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a population-based cohort study. EClinicalMedicine 2023 June 29;61:102065